|
Sex (ref: Male)
|
0.0002
|
0.801 (0.713–0.899)
|
0.0003
|
0.792 (0.698–0.900)
|
|
Age (ref: < 75 years old)
|
0.0024
|
1.389 (1.123–1.717)
|
–
|
–
|
|
Histotype (ref: Other)
|
|
LMS
|
0.0004
|
0.765 (0.659–0.888)
|
0.0010
|
0.765 (0.652–0.897)
|
|
DLPS
|
0.0269
|
1.291 (1.030–1.619)
|
0.2034
|
1.171 (0.918–1.492)
|
|
MPNST
|
0.1368
|
1.273 (0.926–1.751)
|
0.2183
|
1.234 (0.883–1.726)
|
|
SS
|
0.4738
|
1.074 (0.883–1.307)
|
0.0764
|
1.206 (0.980–1.485)
|
|
UPS
|
0.0061
|
1.347 (1.089–1.668)
|
0.1839
|
1.168 (0.929–1.469)
|
|
Grade (ref: < 3)
|
< 0.0001
|
1.692 (1.491–1.920)
|
< 0.0001
|
1.687 (1.483–1.919)
|
|
Number of metastatic sites (ref: 1)
|
0.0136
|
1.200 (1.038–1.387)
|
0.0009
|
1.305 (1.115–1.528)
|
|
Liver metastasis (ref: no)
|
0.1056
|
0.891 (0.774–1.025)
|
–
|
–
|
|
Locoregional treatment (ref: no)
|
< 0.0001
|
0.412 (0.365–0.465)
|
< 0.0001
|
0.400 (0.351–0.455)
|
|
Clinical trial (ref: no)
|
< 0.0001
|
0.750 (0.653–0.862)
|
0.0002
|
0.755 (0.651–0.877)
|
|
Off-label drugs (ref: no)
|
< 0.0001
|
0.791 (0.703–0.890)
|
–
|
–
|
|
Anthracycline (ref: no)
|
0.0046
|
0.838 (0.741–0.947)
|
–
|
–
|
|
Anthracycline in first line (ref: no)
|
0.0127
|
0.861 (0.765–0.968)
|
–
|
–
|
|
Polychemotherapy in first line (ref: no)
|
0.0003
|
0.804 (0.715–0.902)
|
0.0023
|
0.822 (0.724–0.932)
|
